Changes between Version 1 and Version 2 of Research/DesignStudy/SteeringGroup/2020-12-11


Ignore:
Timestamp:
Nov 23, 2020, 9:56:42 AM (4 years ago)
Author:
longkr
Comment:

--

Legend:

Unmodified
Added
Removed
Modified
  • Research/DesignStudy/SteeringGroup/2020-12-11

    v1 v2  
    1 = Temp =
     1CCAP
     2 
     3logged in as longkr
     4Logout
     5PreferencesHelp/GuideAbout Trac
     6HomeResearchCommunicationTeachingTimelineBrowse sourceSearch
     7wiki:Research/DesignStudy/SteeringGroup/2020-09-24
     8UpStart pageIndexHistory
     9LhARA Steering Group meeting #4
     1024th September 2020 10:00 GMT
     11
     12Notes
     13
     14Notes of last meeting and actions arising:
     15KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     16Superceded.
     17KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     18Ongoing.
     19KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     20Ongoing.
     21KL: Ensure one representative per group at the next LhARA SG meeting.
     22Stands.
     23KL: Raise NIHR engagement with K.Gleeson.
     24Done.
     25KL: Seek PPI representative for SG.
     26Done. Welcome G. Jones and H. Hall.
     27KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4.
     28StG: Brm is not a radiotherapy research centre. Shoudl contact Manchester, Oxford, and Liverpool.
     29TG: Also need to contact with relevant medical physics groups.
     30KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
     31Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed.
     32KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4.
     33Ongoing.
     34KL: Write to J.Clarke to ask for support to reach out to relevant industry.
     35Stands.
     36PA: Make contact with MTC to see how to make contact with relevant industry.
     37Stands
     38PA/KL will cooperate in drafting a letter.
     39Stands.
     40KL: Review proposed w/p structure and skills matrix taking into account comments under item 4.
     41Stands.
     42KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
     43Done. Meeting organised between A.Price and R.McLauchlan a success.
     44Update on progress: KL
     45Towards a PPI strategy for LhARA: GJ, HH
     46Main stem of strategy is to raise awareness with public and with patients. Then develop the engagement as the programme progresses.
     47Hard to see anything which would not benefit patients and also the health services. Patient input is vital all at all stages in the development of the programme.
     48Management of PPI will take time. Perhaps means that we need to include some resource. Marsden PPI outreach.
     49HH sits on various PPI advisory groups and can make links top various institutes.
     50Focus on engagement rather than involvement.
     51StG:
     52Agrees re effort involved in getting broad activity. Link to the Royal Marsden will be important.
     53KK:
     54BRC links important.
     55SG expressed it grateful recognition of the efforts of GJ and HH and the PPI representatives in drafting the two Lay Summaries so far. Both are/will be published.
     56Towards a clinician-engagement strategy for LhARA: StG
     57Neil Burnett and Adrian Crellin from Brm meeting might be pursuared to promote activity. Elizabeth Schuster, Rostoc is a researcher into the impact of microbeams.
     58There is a need to reach out to research-active clinicians. Probably should build up a target list in preparation for a webinar. A process such as that adopted by TP for the endstation/diagnostics development would be appropriate.
     59KK:
     60Noted the perception in the community that laser-ion beams are like nuclear fusion -- always 15 years away.
     61Critical to develop clear statement of what what the laser-hybrid technique can do that others cant.
     62Meeting:
     63We agreed to work towards a meeting of the relevant peer groups. TKW agreed to make contact with IoP at "top level".
     64​Transformative Healthcare Technologies second call: KL/All
     65Updated outline presented at the LhARA weekly meeting 22Sep20
     66Discussion included:
     67PPI: GJ/HH
     68Clinician engagement: StG
     69Plan for preparation of proposal
     70Scope
     71Work packages
     72Stakeholders
     73DONMs
     74TBD
     75AoB
     76Agenda
     77
     78Notes of last meeting and actions arising:
     79KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     80Superceded.
     81KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     82Ongoing.
     83KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     84Ongoing.
     85KL: Ensure one representative per group at the next LhARA SG meeting.
     86Stands.
     87KL: Raise NIHR engagement with K.Gleeson.
     88Done.
     89KL: Seek PPI representative for SG.
     90Done. Welcome G. Jones and H. Hall.
     91KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4.
     92KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
     93Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed.
     94KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4.
     95Ongoing.
     96KL: Write to J.Clarke to ask for support to reach out to relevant industry.
     97Stands.
     98PA: Make contact with MTC to see how to make contact with relevant industry. PA/KL will cooperate in drafting a letter.
     99KL: Review proposed w/p structure and skills matrix taking into account comments under item 4.
     100Stands.&&
     101KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
     102Done. Meeting organised between A.Price and R.McLauchlan a success.
     103Update on progress: KL
     104Towards a PPI strategy for LhARA: GJ, HH
     105Towards a clinician-engagement strategy for LhARA: StG
     106​Transformative Healthcare Technologies second call: KL/All
     107Updated outline presented at the LhARA weekly meeting 22Sep20
     108Discussion to include:
     109PPI
     110Clinician engagement:
     111Industrial engagement:
     112Plan for preparation of proposal
     113Scope
     114Work packages
     115Stakeholders
     116Next steps discussion
     117DONMs
     118TBD
     119AoB
     120Last modified 26 seconds ago
     121Attachments (4)
     122
     123       
     124Download in other formats:
     125Plain text
     126Trac PoweredPowered by Trac 1.0.13
     127By Edgewall Software.Visit the Trac open source project at
     128http://trac.edgewall.org/